Home healthcare and the use of medical devices outside of the professional healthcare environment are on the rise. Modern medicine allows us to live longer and provides those with chronic diseases the ability to receive medical care at home. Examples of home-use devices are oxygen concentrators, hospital beds, sleep apnea monitors, body-worn nerve and muscle stimulators, and dialysis machines, just to name a few.
Over the past three decades, researchers have found various applications of a method for attaching molecules to gold; the approach uses chemicals called thiols to bind the materials together. But while this technique has led to useful devices for electronics, sensing and nanotechnology, it has limitations. Now, an MIT team has found a new material that could overcome many of these limitations.
Japanese scientists, using a new material that can be molded into complex, highly conductive 3-D structures with features just a few micrometers across, are able to create shapes the size of a typical bacterium. Combined with state-of-the-art micro-sculpting techniques, the new resin holds promise for making customized electrodes for fuel cells or batteries, as well as biosensor interfaces for medical uses.
Uscom (ASX: UCM) Uscom Limited today signed a deed to acquire all assets of Pulsecor Limited. Pulsecor Limited is a New Zealand company which has developed novel non-invasive central blood pressure measurement methods pioneered at the Weill Cornell Medical College in New York.
The technology at the heart of the next generation of medical devices is critical to our ability to offer comprehensive care in the coming decades. While our current systems of care have served us well thus far, they are crumbling under the pressures of modern expectations of care, economics, scale, and the sheer breadth of medical science.
Charlotte Based Compression And Vacuum Therapy Technology Helps Train Cyclist In Race Across AmericaMay 29, 2013 11:30 am | by PR Newswire | News | Comments
Austrian Cyclist Gerald Bauer will be directly benefiting from Charlotte based HYPOXI therapy and equipment to give him a possible racing edge in the Race Across America. Gerald will specifically use the Charlotte HYPOXI Multispectrum S120 device one week prior to the race and each day after the race. Dr. Fedor Fomin of HYPOXI will be providing the therapy.
A team of researchers from the UPNA/NUP-Public University of Navarre has developed new super resolution and segmentation methods for magnetic resonance images so that they can be applied to the structural study of psychosis. The aim is to be able to identify the differences that are produced in specific parts of the brain in psychotic patients with respect to their healthy relatives or other people.
A research team jointly led by scientists from Cedars-Sinai Medical Center and the University of California, Los Angeles, have enhanced a device they developed to identify and "grab" circulating tumor cells, or CTCs, that break away from cancers and enter the blood, often leading to the spread of cancer to other parts of the body.
The global ultrasound market is forecast to grow by 27 percent over the next five years despite ongoing economic challenges, with emerging healthcare markets key to sustaining future global growth, according to a new report entitled “The World Market for Ultrasound Imaging Equipment – 2013” from IMS Research, now part of IHS Inc. (NYSE: IHS).
Paper is known for its ability to absorb liquids, making it ideal for products such as paper towels. But by modifying the underlying network of cellulose fibers, etching off surface “fluff” and applying a thin chemical coating, researchers have created a new type of paper that repels a wide variety of liquids – including water and oil.
The Food and Drug Administration said Thursday it approved a new blood test from Roche to help doctors diagnose diabetes. The Cobas Integra 800 is a blood test that measures a patient's average blood sugar level over the previous three months. In particular, the test measures an oxygen-carrying blood component known as hemoglobin.
Although colonoscopy exams prevent many colon cancer deathsand are considered the most sensitive method for detecting colorectal cancers, the procedure is not completely effective in preventing cancer cases. EndoChoice has unveiled research that shows that its new Fuse system significantly improves the accuracy of this procedure and greatly reduces the number of adenomas missed by colonoscopists.
Nephosity, a digital health startup that was a member of Rock Health’s second class, has received clearance from the United States Food and Drug Administration (FDA) for their MobileCT Viewer, a software application for diagnostic image viewing on the iPad.
In this video, a representative at Nephosity demonstrates MobileCT, an app for mobile collaborative teleradiology. It allows for a user (such as a doctor or patient) to use their mobile devices to view x-rays, MRIs, etc., and to collaborate with other users (such as other doctors or relatives).
Professor Brian T. Cunningham and his graduate students demonstrate their development of using a smartphone camera as a high resolution spectrophotometer. Cunningham’s group is now collaborating with other groups across campus at the U. of I. to explore applications for the iPhone biosensor.
Researchers and physicians in the field could soon run on-the-spot tests for environmental toxins, medical diagnostics, food safety and more with their smartphones. University of Illinois at Urbana-Champaign researchers have developed a cradle and app for the iPhone that uses the phone’s built-in camera and processing power as a biosensor to detect toxins, proteins, bacteria, viruses, and other molecules.
National Lung Screening Trial investigators also conclude that the 20 percent reduction in lung cancer mortality with low-dose computed tomography versus chest X-ray screening previously reported in the NLST primary paper is achievable at experienced screening centers in the United States.
First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer DetectionMay 23, 2013 10:28 am | by PR Newswire | News | Comments
Hologic, Inc. has announced that the first large-scale observational study in a U.S. clinical practice comparing breast cancer screening with Hologic's 3D mammography technology with conventional 2D mammography alone showed a significant reduction in recall rates and a sizeable increase in cancer detection, particularly invasive cancer, across all breast tissue densities.
TOPS Comprehensive Breast Center Study Validates the Benefits of New 3D Mammography Technology in Breast Cancer ScreeningMay 23, 2013 10:24 am | by The Associated Press | News | Comments
HOUSTON--(BUSINESS WIRE)--May 23, 2013--The first large-scale U.S. study comparing conventional 2D mammography screening exams alone versus 2D mammography with the addition of 3D mammography (breast tomosynthesis) technology has been completed at TOPS Comprehensive Breast Center. The study showed...
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, will display its ForeCYTE Breast Health Test at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, from May 31 through June 4, 2013. Atossa's exhibit will be located in booth 2019...
TEL AVIV, Israel, May 23, 2013 /PRNewswire/ -- Israel Brain Technologies (IBT) has announced the launch of BrainTech Israel 2013, Israel's 1st International Brain Technology Conference, which will take place on October 14th-15th in Tel Aviv, recently ranked as the 2nd most innovative...
The Selenia Dimensions 3D System is comprised of hardware and software upgrades to the Selenia Dimensions 2D full-field digital mammography system, which is FDA approved for conventional mammography. The hardware upgrades produces multiple, low-dose x-ray images of the breast; the software upgrade uses the low-dose x-ray images to create cross-sectional (tomosynthesis) views of the breast.
Cognoptix Test Identifies Alzheimer’s Disease via Beta Amyloid Signature in the Eyes in Proof-of-Concept Clinical TrialMay 22, 2013 12:53 pm | by The Associated Press | News | Comments
ACTON, Mass.--(BUSINESS WIRE)--May 22, 2013--Cognoptix, an emerging medical device company, announced today that its SAPPHIRE II eye test identified Alzheimer’s disease patients via a beta amyloid (“Ab”) signature in their eyes in a 10-subject proof-of-concept clinical trial.
New Data on Cellvizio Presented at DDW 2013 Suggests That Optical Biopsies May Help Confirm and Rule Out Pancreatic Cystic Tumors*May 22, 2013 11:45 am | by The Associated Press | News | Comments
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, today announced that optical biopsies using a microscope so tiny it fits through a small needle show clear cellular-level images inside pancreatic cysts,...
DENVER--(BUSINESS WIRE)--May 22, 2013--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it has entered into a collaboration agreement with Eli Lilly and Company (NYSE: LLY) to develop diagnostic technology in support of a...